Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, proudly announces the successful migration to its newly developed DEA-approved telemedicine operating system. This milestone marks a significant advancement in MangoRx's capabilities, reinf ...

Financial Data and Key Metrics Changes - The company reported year-over-year growth across all key profitability metrics in Q2 2024, including operating income, net income, distributable cash flow (DCF), and adjusted EBITDA [3] - Adjusted EBITDA was $121.1 million in Q2 2024, up from $90.4 million in Q2 2023, while net income increased to $46.1 million from $41.4 million [5] - Distributable cash flow reached $73.1 million in Q2 2024, compared to $54.8 million in the same quarter of 2023, with adjusted DCF at $74.2 million versus $53.3 million [5] - LTM distribution coverage as of June 30 was 1.8x, or 1.6x after factoring in distributions to preferred unitholders [5] Business Line Data and Key Metrics Changes - GDSO product margin increased by $22.4 million to $221.5 million, with gasoline distribution margins rising by $19.4 million to $147.3 million due to higher fuel margins [5][6] - Station operations product margin rose by $3 million to $74.2 million, reflecting successful merchandising initiatives [6] - In the Wholesale segment, product margin increased by $32.2 million to $91.9 million, driven by the acquisition of Motiva terminals and favorable market conditions [6] Market Data and Key Metrics Changes - The company expanded its geographic reach through the acquisition of 29 terminals, doubling storage capacity to 21.4 million barrels [3] - The portfolio of fueling stations and convenience store sites totaled 1,595, with an additional 64 sites operated under a joint venture [6] Company Strategy and Development Direction - The company is focused on maximizing the value from newly acquired assets and exploring opportunities for further investments in both terminal and retail businesses [3][14] - Management emphasized ongoing efforts in merchandising optimization across the entire portfolio, indicating a commitment to continuous improvement [15] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positive momentum entering the second half of 2024, aiming to execute strategic growth objectives and deliver value to unitholders [12] - The retail M&A market remains active, providing opportunities for expansion in the convenience store sector, particularly in Texas [16] Other Important Information - The Board declared a quarterly cash distribution of $0.72 per common unit, representing a 6.7% increase over the prior year [4] - Operating expenses increased by $19.6 million to $130 million, largely due to terminal acquisitions [8] Q&A Session Summary Question: Follow-up on Wholesale investments and opportunities - Management indicated that M&A activity remains active in both terminal and retail businesses, with a focus on maximizing value from existing assets [14] Question: Update on merchandising efforts across stores - Management confirmed that merchandising optimization is an ongoing effort across the entire portfolio, with continuous improvements expected [15] Question: Update on the joint venture in Houston - Management expressed optimism about the joint venture's potential for growth in the retail market, particularly in Texas [16]

Core Insights - Annovis Bio Inc. announced new preclinical data showing the synergistic effect of its lead compound, buntanetap, when combined with the GLP-1 agonist dulaglutide in a mouse model of Alzheimer's disease [1][3] Group 1: Company Overview - Annovis Bio Inc. is a late-stage clinical drug platform company focused on developing therapies for neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease [1][7] - The company targets multiple neurotoxic proteins to improve synaptic transmission and reduce neuroinflammation, aiming to reverse neurodegeneration and restore brain function [6][7] Group 2: Research Findings - The combination of buntanetap and dulaglutide restored cognitive function beyond levels seen in healthy controls, with buntanetap alone restoring cognitive function to 100% and dulaglutide to 80% [3] - The recent data presented at the Alzheimer's Association International Conference indicated that another GLP-1 agonist, liraglutide, decreased cognitive decline in Alzheimer's patients by 18% [2] Group 3: Mechanism of Action - GLP-1 agonists, like dulaglutide, have better blood-brain barrier permeability due to their molecular structure, making them suitable for combination therapy with buntanetap [4] - Buntanetap inhibits the formation of neurotoxic proteins, which is crucial for addressing neurodegeneration in Alzheimer's and Parkinson's diseases [6] Group 4: Executive Commentary - The CEO of Annovis Bio expressed excitement over the significant amplification of dulaglutide's effects on memory and learning when combined with buntanetap, highlighting the potential for improved treatment outcomes [5]

Hims & Hers stock has been surging since May, but has its valuation gotten too rich? Healthcare stocks don't have to be making weight loss drugs to be hot buys due to the rising demand for glucagon-like peptide 1 (GLP-1) treatments. A good example of that is Hims & Hers Health (HIMS -12.85%). Up more than 140% this year, the telehealth company has been a hot buy with investors not only for its impressive growth but also for its ability to help connect patients with GLP-1 drugs. However, the company's strate ...

Patients who received liraglutide had an 18% slower decline in cognitive function after one year of treatment compared to those who received the placebo. Researchers presented the results on Tuesday at the Alzheimer's Association International Conference in Philadelphia, the world's largest meeting for dementia research. Brian B. Bettencourt | Toronto Star | Getty Images Notably, existing research shows that GLP-1s do not bring the risk of brain swelling and bleeding, two side effects that have been linked ...

Jacob Wackerhausen/iStock via Getty Images Therefore, it could end up being that this recombinant protein from Biohaven could have a synergistic effect with current treatment options. This is possible because of the mechanism of action of this drug compared to the other approved ones. In essence, taldefgrobep alfa is a myostatin inhibitor and its goal is to knock down the signaling of myostatin itself. This is important, because overactive myostatin activation inhibits muscle growth. Thus, the mechanism of ...

1. GZR18 injection is an investigational drug and has not yet been approved in China. In this study, the bi-weekly GZR18 injections were generally safe and well tolerated, consistent with the known safety signals of GLP-1 receptor agonists. The most common adverse events were gastrointestinal reactions, most of which were mild to moderate in severity, comparable to other GLP-1 RAs. In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked second overall and first am ...

Cautionary Note Regarding Forward-Looking Statements 1 Year-Two Real-World Analysis of Glucagon-Like Peptide-1 Agonist (GLP-1) Obesity Treatment Adherence and Persistency, Prime Therapeutics/Magellan RX Management, 2024 NEW YORK, July 16, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a national employer to provide its cardiometabolic solution with integrated support for GLP-1s to employees b ...

Core Insights - The analysis focuses on two biotech companies, Altimmune and Viking Therapeutics, which are developing GLP-1-targeted medicines for obesity, aiming to compete with established products from Eli Lilly and Novo Nordisk [8] Company Analysis Viking Therapeutics - Viking's lead candidate, VK2735, has shown promising results in its phase 2b clinical trial, with participants losing an average of 15.6% of their mass over 48 weeks [7][9] - The company is well-capitalized with $963 million in cash and equivalents, and it has no debt, which positions it favorably for commercialization [20] - Viking's pipeline includes non-GLP-1 programs, providing additional avenues for growth and reducing reliance on a single product [13] Altimmune - Altimmune's lead program is nearing the end of phase 2 trials, with strong interim data suggesting a likely continuation to phase 3 trials [11] - The company has $182 million in cash and equivalents, with total expenses of $89 million, indicating it can sustain operations but may need to raise additional funds for commercialization [22] - Altimmune's candidate may preserve muscle mass during weight loss, which could appeal to specific demographics such as seniors and those with mobility issues [21][18] Market Position - Both companies are positioned to capture market share in the obesity treatment sector, with Viking slightly ahead in terms of market readiness [9][19] - The absence of direct competition for Altimmune in its segments may provide a strategic advantage [12] - The potential for both companies to succeed in their clinical trials and secure regulatory approval in the coming years is high, making them attractive investment opportunities [19]

LLY $918.00 52-Week Range $434.34 $928.60 P/E Ratio 135.20 By all accounts, Eli Lilly's Tirzepatide, the active ingredient in Mounjaro and Zepbound, is superior on paper to Semaglutide, the active ingredient in Ozempic and Wegovy, because it targets two hormones compared to one. However, currently in Phase 2 clinical trials, its secret weapon for weight loss targets three hormones as the ultimate triple threat. Eli Lilly operates in the medical sector, facing competition from upcoming GLP-1 contenders from ...